Hans-Henrik Parving
Overview
Explore the profile of Hans-Henrik Parving including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
275
Citations
13652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skriver-Moller A, Moller A, Blond M, Rasmussen D, Genovese F, Reinhard H, et al.
J Diabetes Complications
. 2024 May;
38(6):108765.
PMID: 38749295
Background: This post-hoc study investigated whether biomarkers reflecting extracellular matrix (ECM) turnover predicted cardiovascular disease (CVD), mortality, and progression of diabetic kidney disease (DKD) in individuals with type 2 diabetes...
2.
Brosen J, Agesen R, Alibegovic A, Andersen H, Beck-Nielsen H, Gustenhoff P, et al.
J Diabetes Sci Technol
. 2023 Sep;
19(2):390-399.
PMID: 37671755
Aim: Comparing continuous glucose monitoring (CGM)-recorded metrics during treatment with insulin degludec (IDeg) versus insulin glargine U100 (IGlar-100) in people with type 1 diabetes (T1D) and recurrent nocturnal severe hypoglycemia....
3.
Poulsen C, Rasmussen D, Genovese F, Hansen T, Holm Nielsen S, Reinhard H, et al.
PLoS One
. 2023 Mar;
18(3):e0283296.
PMID: 36930632
Background: Diabetic kidney disease is a major cause of morbidity and mortality. Dysregulated turnover of collagen type III is associated with development of kidney fibrosis. We investigated whether a degradation...
4.
Brosen J, Agesen R, Kristensen P, Alibegovic A, Andersen H, Beck-Nielsen H, et al.
Diabetes Obes Metab
. 2023 Feb;
25(6):1557-1565.
PMID: 36749303
Aim: To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes...
5.
Smeijer J, Koomen J, Kohan D, McMurray J, Bakris G, Correa-Rotter R, et al.
Clin Pharmacol Ther
. 2022 Jul;
112(5):1098-1107.
PMID: 35892316
Plasma exposure of the endothelin receptor antagonist atrasentan varies between individuals and is associated with nephroprotective effects and the risk of heart failure. We examined the influence of genetic polymorphisms...
6.
Smeijer J, Koomen J, Kohan D, McMurray J, Bakris G, Correa-Rotter R, et al.
JACC Heart Fail
. 2022 Jun;
10(7):498-507.
PMID: 35772861
Background: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic...
7.
Brosen J, Agesen R, Alibegovic A, Andersen H, Beck-Nielsen H, Gustenhoff P, et al.
Diabetes Technol Ther
. 2022 Apr;
24(9):643-654.
PMID: 35467938
Nocturnal hypoglycemia is mainly a consequence of inappropriate basal insulin therapy in type 1 diabetes (T1D) and may compromise optimal glycemic control. Insulin degludec is associated with a lower risk...
8.
Waijer S, Gansevoort R, Bakris G, Correa-Rotter R, Hou F, Kohan D, et al.
Clin J Am Soc Nephrol
. 2021 Dec;
16(12):1824-1832.
PMID: 34853062
Background And Objectives: Atrasentan reduces the risk of kidney failure but increases the risk of edema and, possibly, heart failure. Patients with severe CKD may obtain greater absolute kidney benefits...
9.
Pedersen-Bjergaard U, Agesen R, Brosen J, Alibegovic A, Andersen H, Beck-Nielsen H, et al.
Diabetes Obes Metab
. 2021 Oct;
24(2):257-267.
PMID: 34643020
Aim: To investigate whether the long-acting insulin analogue insulin degludec compared with insulin glargine U100 reduces the risk of nocturnal symptomatic hypoglycaemia in patients with type 1 diabetes (T1D). Methods:...
10.
Heerspink H, Xie D, Bakris G, Correa-Rotter R, Hou F, Kitzman D, et al.
J Am Soc Nephrol
. 2021 Sep;
32(11):2900-2911.
PMID: 34551995
Background: Whether early reduction in albuminuria with atrasentan treatment predicts its long-term kidney-protective effect is unknown. Methods: To assess the long-term effects on kidney outcomes of atrasentan versus placebo in...